Clinical Research in Oncology

The standardization and implementation of new endpoints are crucial for the development of novel therapeutic agents. These endpoints help streamline clinical development while maintaining high standards of care for innovative treatments, ultimately leading to improved patient outcomes. 

Pancreatic cancer, predominantly pancreatic ductal adenocarcinoma (PDAC), remains one of the most lethal malignancies, characterized by late diagnosis, aggressive tumor biology, and profound resistance to conventional therapies. Despite advances in surgical techniques and combination chemotherapy regimens such as FOLFIRINOX and gemcitabine-based therapies, survival outcomes remain poor, with five-year survival rates barely exceeding 10%.